|
業務類別
|
-- |
|
業務概覽
|
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE. |
| 公司地址
| 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320 |
| 電話號碼
| +33 155427878 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.dbv-technologies.com |
| 員工數量
| 110 |
| Dr. Pharis Mohideen, M.D. |
Chief Medical Officer |
美元 567.79K |
15/05/2025 |
| Ms. Virginie Boucinha |
Chief Financial Officer and Principal Accounting Officer |
美元 319.31K |
15/05/2025 |
| Mr. Daniel Tasse |
Director and Chief Executive Officer |
美元 600.00K |
15/05/2025 |
|
|
| Dr. Philina Lee, PhD |
Director |
30/10/2025 |
| Dr. Adora Ndu, Pharm.D. |
Independent Director |
15/05/2025 |
| Ms. Mailys Ferrere |
Director |
15/05/2025 |
| Mr. Daniel Tasse |
Director and Chief Executive Officer |
15/05/2025 |
| Dr. Ravi Madduri Rao, M.D. |
Independent Director |
15/05/2025 |
| Ms. Daniele Guyot-Caparros |
Independent Director |
15/05/2025 |
| Ms. Julie O'Neill |
Independent Director |
15/05/2025 |
| Mr. Michel De Rosen |
Non-Executive Chairman of the Board |
15/05/2025 |
| Mr. Michael J. Goller |
Director |
15/05/2025 |
| Mr. Timothy E. Morris |
Independent Director |
15/05/2025 |
|
|
|
|
